Stocks of Keros Therapeutics Inc (NASDAQ:KROS) traded higher last session on Wall Street, up 2.38% to $66.20.
KROS stock price is now 8.18% away from the 50-day moving average and 56.91% away from the 200-day moving average. The market capitalization of the company currently stands at $2.38B.
On December 08, 2023, Wells Fargo recently initiated its ‘Overweight’ rating on the stock quoting a target price of $60, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, Regnante Keith, Chief Financial Officer sold 40,000 shares of the company’s stock on Nov 04 ’23. The stock was sold for $1,811,600 at an average price of $45.29. Upon completion of the transaction, the Chief Financial Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 09 ’23, Chief Financial Officer Regnante Keith sold 20,000 shares of the business’s stock. A total of $908,367 was realized by selling the stock at an average price of $45.42. A total of 25.76% of the company’s stock is owned by insiders.
During the past 12 months, Keros Therapeutics Inc has had a low of $27.02 and a high of $73.00. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 14.25, and a quick ratio of 14.25. The fifty day moving average price for KROS is $61.19 and a two-hundred day moving average price translates $42.19 for the stock.
The latest earnings results from Keros Therapeutics Inc (NASDAQ: KROS) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$1.34, beating analysts’ expectations of -$1.37 by 0.03. This compares to -$1.09 EPS in the same period last year. The net profit margin was -101319.21% and return on equity was -50.19% for KROS.
